Skip to content Skip to footer
Subscribe Now

NEWS

ONO Pharma
Ono Pharmaceutical Reports the P-II (ONO-4578-08) Trial Findings of ONO-4578 in Gastric or Gastroesophageal Junction (G/GEJ) Cancer
Shots: Ono Pharmaceutical has reported the P-II (ONO-4578-08) trial findings of ONO-4578 (EP4 antagonist) regimen for previously untreated, HER2-negative unresectable advanced or recurrent G/GEJ cancer ONO-4578-08 assessed ONO-4578 (40mg, QD, PO) + Opdivo (360mg, Q3W) & CT (S-1 + Oxa or CapOx) vs PBO + Opdivo & CT in G/GEJ cancer pts across Japan, South Korea…
October 10, 2025
Bio-Thera Collaborates with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) Across Canada
Shots: Bio-Thera Solutions has entered into an exclusive commercialization & license agreement with Intas Pharmaceuticals for BAT2506, a biosimilar version of Simponi (golimumab), for Canada The agreement expands their Feb 2025 deal, under which Intas holds US commercialization rights for BAT2506, while Bio-Thera handles its development & manufacturing BAT2506 is an IgG1 monoclonal antibody that targets…
October 10, 2025
Phibro Animal Health Collaborates with Lighthouse Pharmaceuticals for Novel Canine Periodontal Therapy
Shots: Phibro Animal Health has entered into a licensing agreement with Lighthouse Pharmaceuticals to develop & commercialize a therapeutic asset targeting periodontal health in companion animals As per the agreement, Phibro will obtain exclusive rights to develop, manufacture, and commercialize Lighthouse Pharma’s proprietary compound for canine periodontal care, though financial terms were not disclosed The…
October 10, 2025
Celltrion
Celltrion’s Eydenzelt (Biosimilar, Eylea) Receives the US FDA’s Approval to Treat Multiple Retinal Diseases
Shots: The US FDA has approved Eydenzelt, a biosimilar version of Eylea (aflibercept), to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), & diabetic retinopathy Approval was supported by extensive analytical, non-clinical, & clinical data, incl. a P-III trial in DME pts (n=348) comparing Eydenzelt vs Eylea over…
October 10, 2025
Novo Nordisk to Acquire Akero Therapeutics for ~$5.2B, Expanding its MASH Portfolio
Shots: Novo Nordisk will acquire Akero Therapeutics, incl. its lead asset efruxifermin (EFX), to expand its metabolic dysfunction-associated steatohepatitis (MASH) portfolio As per the deal, Novo Nordisk will acquire Akero for $54/share in an all-cash transaction totaling ~$4.7B, along with one non-tradeable CVR of $6/share (~$0.5B) tied to EFX’s US FDA approval for compensated cirrhosis due…
October 10, 2025
Load more